Robert Driscoll
Stock Analyst at Wedbush
(2.97)
# 1,589
Out of 5,093 analysts
153
Total ratings
38.52%
Success rate
1.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $11.64 | +226.46% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $80.06 | -0.07% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $10.37 | +266.44% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $10.73 | +67.83% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $13.17 | +105.01% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.41 | +183.69% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.00 | +500.00% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $17.85 | -4.76% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $13.32 | -9.91% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $8.64 | +270.37% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $35.34 | +47.14% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $22.80 | +22.81% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.75 | +481.82% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $25.80 | +16.28% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.52 | +853.83% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $12.44 | +189.39% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.04 | +957.69% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.45 | +192.13% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.60 | +35.42% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $16.58 | +346.32% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.36 | +49.25% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.27 | +451.18% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $3.87 | +106.72% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.52 | -11.50% | 4 | May 19, 2020 |
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $11.64
Upside: +226.46%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $80.06
Upside: -0.07%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $10.37
Upside: +266.44%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $10.73
Upside: +67.83%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $13.17
Upside: +105.01%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.41
Upside: +183.69%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.00
Upside: +500.00%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $17.85
Upside: -4.76%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $13.32
Upside: -9.91%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $8.64
Upside: +270.37%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $35.34
Upside: +47.14%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $22.80
Upside: +22.81%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.75
Upside: +481.82%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $25.80
Upside: +16.28%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.52
Upside: +853.83%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $12.44
Upside: +189.39%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.04
Upside: +957.69%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.45
Upside: +192.13%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $9.60
Upside: +35.42%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $16.58
Upside: +346.32%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.36
Upside: +49.25%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.27
Upside: +451.18%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $3.87
Upside: +106.72%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.52
Upside: -11.50%